Table S4 from Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations

Authors

Adib, Elio

Klonowska, Katarzyna

Giannikou, Krinio

Do, Khanh T.

15 more author(s)...

Description

Description from Figshare; "Table S4. Inactivating mutations in TSC1/TSC2 and activating mutation in MTOR identified in 30 patients in the clinical trial - clonality and biallelic TSC1/TSC2 inactivation status."

Subject

Clinical Trial, Phase II

Everolimus

Neoplasms/drug therapy

TOR Serine-Threonine Kinases

Tuberous Sclerosis Complex 1 Protein

Tuberous Sclerosis Complex 2 Protein

Access Rights

Free to All